Advertisements
-
Recent Posts
- Response of Campaign for Dignified and Affordable Healthcare to the Delhi Government’s Draft Advisory
- AIDAN’s response to Delhi Government’s Advisory
- AIDAN statement: Concerns regarding the transfer of the Chairman, NPPA
- Health groups irked by Supreme Court order on vaccine PSUs; mull fresh petition
- Response to the announcement by All India Syringes and Needles Manufacturers Association (AISNMA) to voluntarily reduce trade margins to 75% on ex-factory prices
- ACTA AIDAN Annual Meet Book release Clinical Trials Conflict of Interest draft policy Drug Pricing Drug Promotion Essential Drugs essential medicines EU FDA Generic drug Global Health Health India India-EU FTA IPR Letter Machines Marketing Medical Medical Council of India Medicine Medicine pricing Medicines National Pharmaceuticals Pricing Policy Patent Pharma Industry Pharma Policy Photo PIL Polio Price Control Profit Rational Drugs Reports Sec 3 (d) Supreme Court Supreme Court of India TRIPS Vaccine WHO WTO
Blog Stats
- 96,584 hits
Advertisements
For promotion of generic drugs Rule 65(11) of D&C Rules should be amended. Many States violate this rule and the state drug control do not take rather fears to take any action for the violation.